Patent application EP15190230A (EP), filed 2015-10-16
Publication number: EP3156067A1
Title: HIGH AVIDITY HPV T-CELL RECEPTORS
Abstract: [0001]    The present disclosure pertains to novel high avidity antigen recognizing constructs against Human Papilloma Virus antigens. The invention provides novel T cell receptor (TCR) based molecules which are selective and specific for HPV 16/18 proteins E5, E6 and E7. The TCR of the invention, and HPV antigen-binding fragments derived therefrom, are of use for the diagnosis, treatment and prevention of HPV infection, as well as for the diagnosis, treatment and prevention of HPV infection mediated secondary diseases as HPV infection caused cancers, such as cervical, nasopharyngeal or head and neck cancer. Further provided are nucleic acids encoding the proteins of the invention, and recombinant cells expressing the same.
IPC codes: A61K  39/    12            A I
C07K  14/   005            A I
C07K  14/   725            A I
C07K  16/    08            A I
C12N   5/  0783            A I
Claims: number: 1
text: An antigen recognizing construct comprising a complementary determining region 3 (CDR3) having at least 80% sequence identity to an amino acid sequence selected from SEQ ID Nos. 9 to 28.
number: 2
text: The antigen recognizing construct according to claim 1, wherein the antigen recognizing construct is an antibody, or derivative or fragment thereof, or a T cell receptor (TCR), or derivative or fragment thereof.
number: 3
text: The antigen recognizing construct according to claim 1 or 2, which is a T cell receptor, and comprises in its alpha chain a CDR3 having at least 80% sequence identity to an amino acid sequence selected from SEQ ID Nos. 9, 10, 12, 14, 16, 18, 21, 23, 25, 27, and/or comprises in its beta chain an CDR3 having at least 80% sequence identity to an amino acid sequence selected from SEQ ID Nos.11, 13, 15, 17, 19, 20, 22, 24, 26,28.
number: 4
text: The antigen recognizing construct according to any of claims 1 to 3, which is a TCR, or a fragment thereof, composed of a TCR α and a TCR β chain, wherein said TCR comprises the CDR1 to 3 sequences as comprised in SEQ ID NO: 29 and 31, or 30 and 31; or 32 and 33; or 34 and 35; or 36 and 37; or 38 and 39 ; or 38 and 40; or 41 and 42; or 43 and 44; or 45 and 46; or 47 and 48.
number: 5
text: The antigen recognizing construct according to any of claims 1 to 4, which is a TCR, or a fragment thereof, composed of a TCR α and a TCR β chain, wherein said TCR comprises the variable sequences according to SEQ ID NO: 29 and 31, or 30 and 31; or 32 and 33; or 34 and 35; or 36 and 37; or 38 and 39; or 38 and 40; or 41 and 42; or 43 and 44; or 45 and 46; or 47 and 48.
number: 6
text: A nucleic acid encoding for an antigen recognizing construct according to any one of claims 1 to 5.
number: 7
text: A vector comprising a nucleic acid according to claim 6.
number: 8
text: A host cell comprising an antigen recognizing construct according to any one of claims 1 to 5, or a nucleic acid according to claim 6, or a vector according to claim 7.
number: 9
text: The host cell according to claim 8, which is a lymphocyte, preferably a T lymphocyte, such as a CD4 or CD8 positive T-cell.
number: 10
text: The antigen recognizing construct according to any one of claims 1 to 5, or a nucleic acid according to claim 6, or a vector according to claim 7, or a host cell according to any one of claims 8 or 9, for use in medicine.
number: 11
text: The antigen recognizing construct, or the nucleic acid according, or the vector, or the host cell according to claim 10, for use in the diagnosis, prevention, and/or treatment of an infectious disease or a proliferative disease, such as a malignant or benign tumor disease.
number: 12
text: The antigen recognizing construct, or the nucleic acid according, or the vector, or the host cell according to claim 10 or 11, wherein the use in medicine is a use in immune therapy, preferably in adoptive T cell therapy.
number: 13
text: Anin vitro method for the manufacturing of an HPV specific antigen recognizing construct (ARC) expressing cell line, comprising
number: 14
text: The method according to claim 13, wherein said ARC is an ARC according to any one of claims 1 to 5.
number: 15
text: The method according to claim 13 or 14, wherein said cell is a mammalian, in particular a human, T-cell.
number: 16
text: The method according to any of claims 13 to 15, further comprising the purification of the ARC from the cell and, optionally, the reconstitution of the translated ARC-fragments in a T-cell.
Office action: search_report, dated 2017-04-19
Prior art cited: ref_id: US5545806A
ref_type: patent
severity: background
ref_id: US5569825A
ref_type: patent
severity: background
ref_id: US5714352A
ref_type: patent
severity: background
ref_id: US2002197266A1
ref_type: patent
severity: background
ref_id: - KOHLER; MILSTEIN, EUR. J. IMMUNOL, vol. 5, no. 51, 1976, pages 1 - 519
ref_type: npl
severity: background
ref_id: - "Antibodies: A Laboratory Manual", 1988, CSH PRESS
ref_type: npl
severity: background
ref_id: - "Immunobiology", 2011, GARLAND PUBLISHING
ref_type: npl
severity: background
ref_id: - HASKARD; ARCHER, J. IMMUNOL. METHODS, vol. 74, no. 2, 1984, pages 361 - 67
ref_type: npl
severity: background
ref_id: - RODER ET AL., METHODS ENZYMOL, vol. 121, 1986, pages 140 - 67
ref_type: npl
severity: background
ref_id: - HUSE ET AL., SCIENCE, vol. 246, 1989, pages 1275 - 81
ref_type: npl
severity: background
ref_id: WO2012038055A1
ref_type: patent
severity: background
ref_id: WO2012038055
ref_type: patent
severity: background
Final disposition: pending (2017-04-19)